The world
of the infinitely small

"Game-Changing" spray to protect babies against whooping cough

BPZE1, a candidate nasal vaccine against pertussis originally developped by Camille Locht, Nathalie Mielcarek, and their colleagues at CIIL, is currently being evaluated in adolescents in Australia and in UK.

The clinical development of BPZE1 is supported by ILiAD Biotechnologies, LLC which has signed scientific collaboration and worldwide licence agreements with Institut Pasteur de Lille and INSERM for the BPZE1 technology.